NCT05617313 - Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

June 26, 2025

Study Completion Date

June 26, 2025

Conditions

Non Small Cell Lung CancerMetastatic NSCLCRecurrent Non Small Cell Lung Cancer

Interventions

DRUG

Pembrolizumab

200 mg intravenously on Day 1 of cycle.

DRUG

GT103

10mg/kg taken intravenously on Day 1 of cycle.

Trial Locations (6)

University of Virginia Health System, Charlottesville

Duke Cancer Institute, Durham

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

Karmanos Cancer Center (Wayne State University), Detroit

University of Illinois Cancer Center, Chicago

Summit Health, Berkeley Heights